Hiding the road signs that lead to tumor immunity

por Schaer, David A., Lesokhin, Alexander M., Wolchok, Jedd D.
Publicado 2011

Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

por Schaer, David A, Hirschhorn-Cymerman, Daniel, Wolchok, Jedd D
Publicado 2014

Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope

por Schaer, David A., Li, Yongbiao, Merghoub, Taha, Rizzuto, Gabrielle A., Shemesh, Amos, Cohen, Adam D., Li, Yanyun, Avogadri, Francesca, Toledo-Crow, Ricardo, Houghton, Alan N., Wolchok, Jedd D.
Publicado 2011

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

por Cohen, Adam D., Schaer, David A., Liu, Cailian, Li, Yanyun, Hirschhorn-Cymmerman, Daniel, Kim, Soo Chong, Diab, Adi, Rizzuto, Gabrielle, Duan, Fei, Perales, Miguel A., Merghoub, Taha, Houghton, Alan N., Wolchok, Jedd D.
Publicado 2010

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models

por Li, Yanxia, Amaladas, Nelusha, O’Mahony, Marguerita, Manro, Jason R., Inigo, Ivan, Li, Qi, Rasmussen, Erik R., Brahmachary, Manisha, Doman, Thompson N., Hall, Gerald, Kalos, Michael, Novosiadly, Ruslan, Puig, Oscar, Pytowski, Bronislaw, Schaer, David A.
Publicado 2022

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combinat...

por Holmgaard, Rikke B., Schaer, David A., Li, Yanxia, Castaneda, Stephen P., Murphy, Mary Y., Xu, Xiaohong, Inigo, Ivan, Dobkin, Julie, Manro, Jason R., Iversen, Philip W., Surguladze, David, Hall, Gerald E., Novosiadly, Ruslan D., Benhadji, Karim A., Plowman, Gregory D., Kalos, Michael, Driscoll, Kyla E.
Publicado 2018

Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab

por Callahan, Margaret K, Horak, Christine E, Curran, Michael A, Hollman, Travis, Schaer, David A, Yuan, Jianda, Lesokhin, Alexander M, Kitano, Shigehisa, Hong, Quan, Ariyan, Charlotte E, Busam, Klaus J, Feely, William, Jure-Kunkel, Maria, Grosso, Joseph, Simon, Jason S, Korman, Alan J, Wigginton, Jon M, Gupta, Ashok K, Zhang, Xiaoling, Phillips, Therese, Simmons, Pauline, Sznol, Mario, Wolchok, Jedd D
Publicado 2013